- |||||||||| LB2102 / Legend Biotech
Phase 1 study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1035;
P1
3 4 Preclinical studies of LB2102, an autologous DLL3-directed CAR-T cell, have demonstrated DLL3-specific antitumor effects with a low risk of on-target/off-tumor toxicities and off-target/off-tumor toxicities...Subjects may receive optional bridging therapy followed by lymphodepletion chemotherapy with fludarabine and cyclophosphamide for 3 days...The objectives of the study include characterization of safety and tolerability, evaluation of the recommended phase 2 dose, and assessment of preliminary antitumor activity. US sites will begin enrollment in fall 2023.
|
